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Abstract 
The zinc importer LIV-1, also known as ZIP6, is widely distributed, mainly in 
hormonally controlled tissues such as breast, prostate, kidney, and pituitary. Attention 
has focused on its role in breast cancer, especially its regulation by estrogen and 
epidermal growth factor (EGF) and its link to the Epithelial–Mesenchymal Transition 
(EMT) marker, E-cadherin (CDH1). EMT is important for tumor progression and 
metastasis and therefore a potential target for cancer therapy. CDH1 expression is 
under complex control, including by two transcriptional repressors, Snail and Slug. 
Similar to CDH1, MMP-9 is also a cancer progression marker. Elevated MMP-9 
expression has been linked to increased metastasis and tumor stage. 
In the present study, we investigated the relationship between LIV-1 and CDH1 
in prostate cancer cell lines, LNCaP and DU145. Cells were treated with or without 
10ng/ml EGF for 24 hours, and the mRNA and protein expressions of LIV-1 and 
CDH1 were analyzed by two-step RT-PCR and western blot, respectively. In both 
DU145 cells and LNCaP cells, EGF induced LIV-1 protein expression by about 20% 
and decreased CDH1 mRNA and protein by approximately 40%. However, no 
significant change in LIV-1 mRNA was seen with EGF treatment, indicating a 
post-transcriptional mechanism. EGF also promoted proliferation in the two cell lines. 
LIV-1 shRNA transfection was used to understand whether LIV-1 knockdown 
would influence CDH1. LIV-1shRNA vectors decreased the LIV-1 mRNA and 
protein expression in DU145 cells by around 40%. The effects of LIV-1 knockdown 
on CDH1, Snail, Slug and MMP-9 mRNA expression were also measured. LIV-1 
 xii 
 
knockdown increased CDH1 mRNA (80%), while it decreased the expression of Snail 
mRNA (60%) and MMP-9 mRNA (40%) significantly. There was no significant 
change observed in Slug mRNA expression. It was also found that LIV-1 knockdown 
inhibited cell proliferation of DU145 cells, suggesting that LIV-1 may contribute to 
the EGF-stimulated cell proliferation.  
In summary, this study established an inverse relationship between LIV-1 
expression and CDH1 in prostate cancer cells. LIV-1 could be a potential biomarker 
and a therapeutic target in prostate cancer progression and metastasis study. 
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Chapter 1: Literature Review 
1.1 Zinc in human physiology 
Zinc is present universally in body tissues and fluids. The total body zinc content 
has been estimated to be 30 mmol (2 g). Zinc in skeletal muscle accounts for 
approximately 60% of the total body zinc content and bone mass for approximately 
30%. The concentration of zinc in lean body mass is approximately 0.46mmol/g (30 
mg/g). Plasma zinc has a rapid turnover rate and it represents only about 0.l% of total 
body zinc content. This level is under tight homeostatic control. High concentrations 
of zinc are found in the choroid of the eye as well as in prostatic fluids. [1] 
Zinc is necessary for normal biochemical functions in association with proteins, 
such as catalytic, structural and regulatory. [2] In terms of catalytic effects, zinc is 
required by more than 50 enzymes. Removal of zinc from zinc metalloenzymes can 
cause activities to decrease and adding back zinc can restore enzyme activities. The 
structural role of zinc was established by the discovery of the zinc finger motif, which 
is contained in all kinds of proteins, such as those participating in cellular 
differentiation or proliferation, signal transduction, cellular adhesion, or transcription. 
Zinc is also involved in maintaining structures of some enzymes, for instance, CuZn 
superoxide dismutase, where copper is at the active site and zinc maintains the 
enzymatic structure. Another essential zinc function is to regulate gene expression. 
More than 2000 transcription factors need zinc to maintain their structural integrity 
and ability to bind to DNA. [2] 
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Zinc is essential for various physiological processes, such as cell proliferation, 
reproduction, immune function and defense against free radicals. [3] The symptoms 
of zinc deficiency include impaired growth, loss of hair, thickening and 
hyperkeratinization of the epidermis, and testicular atrophy in humans. Severe zinc 
deficiency can affect various organs, such as the gastrointestinal, central nervous, 
immune, skeletal and reproductive systems. [4] Chronic diseases, such as 
gastrointestinal disorders, renal disease, sickle cell anemia, some cancers, pancreatic 
insufficiency and autoimmune arthritis, have been shown to cause suboptimal zinc 
status in humans. [4] 
Zinc deficiency increases lipid peroxidation in mitochondrial and microsomal 
membranes which makes zinc beneficial to the integrity of the subcellular organelles. 
Since zinc has protective efficiency in regulating the activities of antioxidant 
enzymes, thyroid hormones, and liver marker enzymes, it is also essential to normal 
cell physiological functions. [5] 
 
1.2 Zinc in cancer 
  The role of zinc in cancer has received increasing attention. The link between zinc 
deficiency and cancer progression has been established in human, animal and cell 
culture studies. [3] It was found as early as 1976 that primary osteosarcoma patients 
had elevated serum zinc, while patients with metastases had depressed zinc levels. [6] 
Zinc is essential to various enzymes and transcription factors that regulate key 
cellular functions. [7] Insufficient accessibility to intracellular zinc could result in a 
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decrease of activities of those zinc-dependent proteins involved in the maintenance of 
DNA integrity and may contribute to the development of cancer. [7] For instance, 
zinc is required for site-specific DNA binding and proper transcriptional activation of 
the tumor suppressor protein p53. Both insufficient zinc and excess zinc could cause 
p53 to miss-fold and result in functional loss. [7] Zinc deficiency has also been shown 
to upregulate expression of another tumor suppressor protein nuclear factor κB 
(NF-κB) in rat glioma C6 cells. [5] It has been suggested that a decrease in cellular 
zinc alone causes DNA damage and impairs DNA damage response mechanisms, 
resulting in a loss of DNA integrity and the potential for increased cancer risk. [5] 
There are many reports of abnormal zinc levels in serum and malignant tissues of 
patients with various types of cancer. In breast cancer, for instance, tissue zinc 
concentrations were increased greatly, however, in kidney carcinoma, concentrations 
were decreased markedly. [8] Similar to kidney, zinc content in malignant prostate 
tissues are significantly lower than the levels found in normal prostate and benign 
prostate hyperplasia. [9] 
The reduced ability of malignant cells to accumulate zinc is one of the most 
important factors in the development and progression of prostate malignancy. [10] 
The peripheral zone glandular secretory epithelium in the prostate accumulates 
extraordinarily high levels of zinc, three to ten times higher than that of other soft 
tissues. This is special because mammalian cells generally need to avoid the 
accumulation of high zinc, especially mobile reactive zinc which is toxic. However in 
the peripheral zone of the prostate, an especially high mitochondria zinc level is 
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essential to inhibit m-aconitase activity which can prevent the oxidation of citrate and 
lead to the accumulation and secretion of citrate. [10] The suppressed citrate oxidation 
caused by inhibition of m-aconitase is lethal in other mammalian cells, since it 
eliminates the coupled energy production that normally occurs from Krebs cycle 
oxidation. [10] Without citrate oxidation, 14 Adenosine-5'-triphosphate (ATP) are 
produced from one glucose, compared with 38 ATP when citrate oxidation exists. The 
malignant prostate cells become energy-efficient cells in the absence of high zinc 
concentration, in contrast to the energy-inefficient, citrate-producing cells. Additional 
energy required for the malignant cell to perform its potential malignant activities is 
produced without the inhibition of zinc on m-aconitase activity. [10] 
Findings of an association between zinc and prostate cancer risk have been 
inconsistent. One study of vitamin and mineral supplement use found that zinc 
supplements had a protective function for prostate cancer. [11] In a population-based 
case-control study, little association was found between dietary zinc intake and 
prostate cancer. [12] However, in one follow-up study, it was found that chronic zinc 
oversupply could increase the risk of advanced prostate cancer. [13] Similarly, 
another case-control study done in Italy found a direct association between high zinc 
intake and prostate cancer risk, particularly for advanced cancers. [14] Different 
methods of acquiring dietary zinc intake data could affect the results but it is still not 
clear if zinc supplements can reduce or elevate prostate cancer risk. 
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1.3 zinc transporters  
There are two families of zinc transporters in humans. One is the ZnT (SLC30) 
family of transporters with 10 members, which carry zinc from the cytoplasm into the 
organelles or outside to the extracellular space. The other is the ZIP (SLC39) family 
with 14 members, which are responsible for taking zinc from the extracellular space 
or organellar lumen into the cytoplasm. [15] 
Some of the zinc transporters have wide tissue distributions, such as ZnT1 and 
ZIP1. But many others have restricted tissue expressions. For instance, ZnT5 mRNA 
is highly expressed in human endocrine pancreas, ovary, prostate, and testis tissues. 
Meanwhile, the liver, brain, and small intestine have the highest levels of ZnT6 
mRNA over other tissues or organs. In addition, mRNA and protein concentrations of 
ZnT6 differed within a tissue, which suggested some undefined processing step. [16] 
Several ZnT and ZIP family members are major factors in regulation of zinc 
homeostasis, such as ZnT1, ZIP4, and ZIP5 in intestinal zinc transport, ZIP10 and 
ZnT1 in renal zinc reabsorption, and ZIP5, ZnT2, and ZnT1 in pancreatic release of 
endogenous zinc. Many of them are also involved in other physiological functions, for 
example, ZnT2 in lactation, ZIP14 in the hypozincemia of inflammation, ZIP6, ZIP7, 
and ZIP10 in metastatic breast cancer, and ZnT8 in insulin processing and as an 
autoantigen in diabetes. [15] 
The ZnT4 Zn transporter, expressed in breast epithelial cells, is responsible for the 
inherited zinc deficiency observed in lm (lethal milk) mice, showing that ZnT4 is 
required to supply zinc in breast milk. In addition, human breast-fed infants studies 
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have also revealed a potential role of ZnT2 in the transport of zinc to milk. 
The mRNA and protein of ZIP4 were regulated in response to zinc availability and 
mutations in ZIP4 cause acrodermatitis enteropathica, a rare recessive-lethal human 
genetic disorder. [17] A number of studies have found that the expression levels of 
zinc transporters in human tumors correlate with their malignancy, suggesting that 
alteration of intracellular zinc homeostasis can contribute to the severity of cancer. 
These findings indicate that regulation of zinc homeostasis by zinc transporters plays 
important roles, disruption of which may lead to disease states. [4] 
 
1.4 Zinc transporters in cancer 
Many zinc transporters, such as ZIP4, ZIP6, ZIP7, and ZIP10, have been shown to 
be aberrantly expressed in various cancers. For instance, the expression of ZIP4 is 
activated in pancreatic and hepatocellular cancers. [18-21] In a nude mouse model 
with orthotopic xenografts, silencing of ZIP4 by RNA interference in pancreatic 
cancer cell lines reduced incidence of tumor metastasis, downsized the tumor grade, 
and significantly increased their survival rate. [18] Knockdown of ZIP4 in mouse 
Hepa cells significantly activated apoptosis and modestly slowed progression from 
G0/G1 to S phase when cells were released from hydroxyurea block into 
zinc-deficient medium. It was shown that knockdown of ZIP4 in Hepa cells depressed 
their migration; moreover ZIP4 overexpression in Hepa cells and MCF-7 cells 
enhanced migration. [19] In another study, treatment with physiological 
concentrations of zinc increased the abundance of ZnT-1 mRNA in a rat insulinoma 
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and two human ductal adenocarcinoma cell lines but not in normal human islet cells. 
[22] However, the more significant correlations were found between zinc transporters 
and breast and prostate cancers. 
 
1.4.1 Zinc transporters and breast cancer 
In the United States, breast cancer is the most common malignant tumor expected 
to occur in women, accounting for 28% of incident cases. It is also the second leading 
cause of cancer death in women, following lung and bronchus cancer. [23] ZIP6, 
ZIP7, and ZIP10 are all suspected to be involved in metastatic breast cancer. [20, 21, 
24, 25] 
ZIP7 expression can be enhanced by exogenous zinc in a tamoxifen-resistant 
breast cancer model (TamR cells). Knockdown of ZIP7 with small interfering RNA 
terminated the activation of epithelial growth factor receptor (EGFR)/IGF-I 
receptor/Src signaling. [25] In cancer, the abnormal balance between cell death and 
survival makes cancer cells survive under condition that would normally induce 
apoptosis. EGF provides a strong cell survival signal and offers antiapoptotic ability 
to promote cancer cell survival in inappropriate environments. [26] 
The zinc transporter ZIP10 plays an essential role in the migratory activity of 
highly metastatic breast cancer as well. Screening of clinical samples for ZIP10 
mRNA expression indicated that ZIP10 was significantly correlated with the 
metastasis of breast cancer to the lymph nodes. In addition, the expression of ZIP10 
mRNA was higher in the invasive and metastatic breast cancer cell lines compared 
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with less metastatic ones. In in vitro cell migration assays, the depletion of ZIP10 and 
intracellular zinc inhibited the migratory activity of invasive and metastatic breast 
cancer cell lines MDA-MB-231 and MDA-MB-435S. [24] 
The zinc transporter LIV-1, also known as ZIP6, is estrogen regulated and present 
in greater concentration in estrogen receptor–positive breast cancers as well as in 
tumors that spread to the lymph nodes. [27] LIV-1 has been associated with signal 
transducer and activator of transcription 3 (STAT3), a molecule linked with breast 
cancer progression. This association was first observed in zebrafish embryos where 
LIV-1 was shown to be the downstream target of STAT3 and essential for the nuclear 
localization of another transcription factor, Snail, which causes loss of cell adhesion 
by reducing adherence proteins. [21] Further evidence for an involvement of LIV-1 
with Snail was provided by the observation that LIV-1 siRNA reduced HeLa cell 
invasion via a Snail pathway. [20] 
 
1.4.2 Zinc transporters in prostate cancer 
In the United States, prostate cancer is the most common malignant tumor 
expected to occur in men, accounting for 28% of incident cases. It is also the second 
leading cause of cancer death in men, after lung and bronchus cancer. [23] 
Growth of human prostate cancer cells, LNCaP and PC-3, was inhibited by zinc 
treatment in a dose-dependent manner. [28] Up-regulated gene expression of 
metallothioneins (MTs) and ZnT1 in both cell lines were observed after zinc 
treatment. Since BPH (Benign prostatic hyperplasia) accumulates much more zinc 
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than prostate malignant tissue, the overall balance of zinc is decreased in the prostate 
cancer cells. It was not surprising that compared with BPH, prostate cancer tissues 
expressed significantly lower levels of ZnT1 gene. [28] ZnT4 expression also reduced 
in malignant prostate tissue compared to normal and benign prostate tissue. [29] 
Similarly, mRNA and protein expressions of the zinc uptake transporter, ZIP1, are 
significantly down-regulated in prostate adenocarcinomatous tissue compared with 
normal prostate tissue. These changes occur early in malignancy and are maintained 
through its progression in the peripheral zone. [30] However, overexpressed ZIP1 in 
PC-3 prostate cancer cells results in significant inhibition of NF-kB activity and 
induced secretion of NF-kB-controlled tumorigenic cytokines, such as IL-6 and IL-8. 
NF-kB-regulated genes have an established role in malignant transformation, 
metastatic progression of prostate cancer, and resistance to therapeutic regimens. 
Moreover, ZIP1 overexpression induces suppression of prostate tumor growth in a 
xenograft model. [31] It has been shown that both ZIP2 and ZIP3 are down regulated 
in malignant cells in situ as demonstrated for ZIP1. [32] In contrast to the ZIP1 
localization at the basolateral membrane, ZIP2 and ZIP3 transporter proteins were 
localized predominantly at the apical cell membrane. It was proposed that ZIP2 and 
ZIP3 appeared to be associated with the re-uptake of zinc from prostatic fluid. [32]  
 
1.5 The zinc importer LIV-1 and cancer 
The zinc importer LIV-1 is estrogen-regulated and expressed universally, mainly 
in hormonally controlled tissues such as breast, prostate, placenta, kidney, pituitary 
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and corpus callosum. [27] One investigation in human breast cancer patients found 
that LIV-1 mRNA and protein expression levels are weakly correlated, indicating 
posttranscriptional regulations. [33] In contrast to the usual finding that LIV-1 is 
found in increased amounts in estrogen receptor–positive breast cancer as well as in 
tumors that spread to the lymph nodes[27], another study found that LIV-1 mRNA 
had a trend to lower expression in tumors with lymph node metastasis, although this 
was not significant at the 5% level. [33] Meanwhile high LIV-1 protein expression 
seems to be associated with a longer relapse free and overall survival in breast cancer 
patients with invasive ductal carcinoma. A negative correlation of LIV-1 protein but 
not mRNA levels with tumor size, grade and stage reflected an association of LIV-1 
protein expression with less aggressive tumors. [33] 
LIV-1 has been identified as a gene whose expression is stimulated by estrogen 
treatment in MCF-7 and ZR-75 breast cancer cells. [27] An investigation of LIV-1 
expression in clinical breast-tumour populations revealed its significant correlation 
with estrogen receptor status. [27] LIV-1 mRNA correlation with the estrogen 
receptor and its regulation by the receptor have been reported in several studies. [27, 
33]  
LIV-1 has been shown to contain a novel potential metalloprotease motif similar 
to that in the MMPs (matrix metalloproteases), which have an important and 
well-documented role in metastasis. [34] Recently, it was found that overexpression 
of LIV-1 in prostate cancer ARCaPE cells resulted in elevated MMP-2 and MMP-9 
proteolytic enzyme activities. [35] 
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In zebrafish gastrula organizer, LIV-1 was shown to control 
epithelial-mesenchymal transition (EMT) by being a downstream target of the 
transcription factor STAT3, which has a proven role in the development of cancer. 
LIV-1 was essential for the nuclear localization of the zinc finger transcription factor 
Snail, a master regulator of EMT. [21] The significant association between LIV-1, 
Snail and CDH1 suggested a link between the LIV-1 and EMT in breast cancer. 
 
1.6 EGF and EGFR 
Cancer cells have a characteristic ability to survive under conditions that would 
normally induce apoptosis. Epidermal growth factor (EGF) provides a strong cell 
survival signal and cancer cells promote their survival in inappropriate environments 
through this type of survival signaling. [36] 
The EGF receptor (EGFR) is a transmembrane protein that regulates the 
intracellular effects of ligands such as EGF and transforming growth factor-α 
(TGF-α). [37] With ligand binding to the EGFR extracellular domains, the proportion 
of dimerized receptor increases and the enzymatic activity of its intracellular tyrosine 
kinase domain is induced dramatically. The EGFR exerts its function in the cellular 
environment directly or indirectly through its tyrosine kinase activity. [37] Increased 
expressions of the ligands and/or receptors, as well as ligand-independent receptor 
activation, have been found in many epithelial cancers, especially gliomas and breast, 
pancreas, and liver carcinoma. Human carcinomas frequently express high EGFR and 
this has been associated with a more invasive clinical behavior. Moreover, activation 
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of high levels of EGFR in nonmalignant cell lines can lead to a transformed 
phenotype. [38] 
Multiple signalling pathways can be activated by EGFR, such as the PI3K/AKT, 
RAS/ERK and JAK/STAT pathways. [26] STAT3 and AKT activation correlated 
markedly with EGFR status in malignant astrocytic gliomas. [39] A significantly 
positive correlation between nuclear STAT3 and EGFR expression in breast cancers 
was also reported. [36] STAT3 activation has been shown to play a role in 
oncogenesis and activated STAT proteins are found in human cancer. STAT proteins 
constitute a family of transcription factors that are activated by cytokine and 
non-cytokine receptors. Activation of STAT causes tyrosine phosphorylation, 
dimerization and translocation from the cytoplasm to the nucleus. [36] 
 
1.7 EMT and E-cadherin (CDH1) 
EMT is a rapid and mostly reversible change of cell phenotype. [40] During this 
process, epithelial cells loosen their cell–cell adhesion structures such as adherens 
junctions and desmosomes, modulate their polarity and rearrange their cytoskeleton. 
As a result, they become isolated, motile and resistant to apoptosis. [40] EMT has 
been recognized as a critical phase of embryonic development in animal species. [41] 
Such EMT-like processes are also evoked in tumor progression and metastasis. [40] 
Many in vitro studies show that various carcinoma cell lines undergo EMT or partial 
EMT.  EMT leads to the dissemination of single carcinoma cells from the sites of the 
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primary tumors. More generally, EMT might be involved in the dedifferentiation 
process that causes malignant carcinoma. [41] 
Several signal-transduction pathways for EMT have been identified based on 
research conducted in embryonic model systems and in normal and transformed cell 
lines, including the activation of several receptor tyrosine kinases and transforming 
growth factor-β receptors. [42] Transcriptional repressors of CDH1 are induced in 
these pathways, leading to the loss of the epithelial phenotype. Declining expression 
of CDH1 mRNA and protein are hallmarks of EMT, both in embryonic development 
and in cancer progression. [42] Down-regulation of CDH1 is associated with cell–cell 
dissociation and invasion in pancreas, prostate and mammary gland mouse cancer 
models. [40] CDH1 is required for the maintenance of stable junctions and regarded 
as one of the hallmarks of the epithelial phenotype. In epithelial cells, early contacts 
are mediated by CDH1 molecules that cluster into small junctional complexes, which 
then expand to establish stable adherens junctions and promote the formation of 
desmosomes. Loss of CDH1 expression seems to be strongly involved in EMT since 
there is a direct link between lack of CDH1 production and loss of the epithelial 
phenotype. [41] 
Another cadherin, N-cadherin, by contrast, is produced in some carcinoma cells 
that have lost CDH1 and, in these cells, N-cadherin appears as a weak intercellular 
adhesion system. [41] 
Specific transcription factors, in particular Snail (Snail1), Slug (Snail2), Twist, 
SIP1/Zeb and E47, negatively regulate CDH1 expression. These factors participate in 
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most physiological EMT situations, and their overexpression in epithelial cells usually 
induces EMT. [40] 
 
1.8 Snail and Slug 
During tumor progression, various mechanisms can inactivate or silence CDH1, 
such as somatic mutations, promoter hypermethylation, histone deacetylation, and, 
importantly, transcriptional repression. Several EMT-inducing developmental 
regulators repress CDH1 transcription by binding with specific E-box domains in the 
proximal CDH1 promoter. [42] Most prominent are the Snail-related zinc-finger 
transcription factors Snail and Slug, the repressors ZEB-1 and ZEB-2. [42] 
Endogenous Snail protein is present in invasive mouse and human carcinoma cell 
lines and tumors in which CDH1 expression has been lost. Epithelial cells that 
overexpressed Snail showed a fibroblastoid phenotype and acquired tumorigenic and 
invasive properties. [43] In pancreatic cancer, Snail and Slug are expressed, but not in 
normal tissue. [44]. It was also found Slug and Snail correlated negatively with CDH1 
in transformed breast cell lines. [45] Inconsistent correlations between Snail 
expression and tumor progression in human breast cancer have been seen in another 
study where reduced Snail expression corresponded with higher tumor grades. [46] 
 
1.9 MMP-9 
Controlled degradation of extracellular matrix (ECM) is critical for the growth, 
invasion, and metastasis of malignant tumors, and for tumor-induced angiogenesis. 
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[47] Because of their capacity to degrade ECM, resulting in migration of endothelial 
cells, matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9 are known 
to play a role in angiogenesis, tumor growth and metastasis. [48] Both MMP-2, also 
known as gelatinase A, and MMP-9, also known as gelatinase B, are 
cancer-associated, secreted, zinc-dependent endopeptidases, belonging to the 
gelatinase subgroup of MMP. [49] 72-kDa MMP-2 is expressed in various cell types, 
such as osteoblasts, monocytes, and different types of transformed cells. 92-kDa 
MMP-9 is produced by, for instance, normal alveolar macrophages, osteoclasts, 
invading trophoblasts, and several types of transformed cells. [49]  
Besides extracellular matrix, MMP-2 and MMP-9 cleave many different targets, 
such as cytokines, growth factors and cytokine/growth factor receptors which in turn 
regulate key signaling pathways in cell growth, migration, invasion, inflammation and 
angiogenesis. [49] Expression of MMP-9 is induced at the transcriptional level, by 
growth factors and cytokines, oncogenes, hormones, and contact to the ECM. For 
instance, inhibition of the tumor repressor protein NF-κB reduced the expression of 
MMP-9 in vascular smooth muscle cells. [50] It was found in the MDCK epithelial 
cell line that MMP-9 transcription is also activated in response to Snail 
overexpression. [51] 
Elevated levels of MMP-2 and/or MMP-9 have been reported in many kinds of 
cancers, such as breast, brain, ovarian, pancreas, colorectal, bladder, prostate and lung 
cancers. Since they are overexpressed in a variety of malignant tumors and their 
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expression and activity are often associated with tumor aggressiveness and a poor 
prognosis, they are regarded as cancer biomarkers. [49] 
MMPs have been shown to play a role in the processes of tumor angiogenesis, 
tumor growth and metastasis, albeit that these processes are intermingled with each 
other. [48] Elevated MMP-9 expression has been linked to increased metastasis and 
tumor stage in a number of studies, e.g. malignant versus benign breast tumors and 
advanced versus benign ovarian tumors. In several invasive cell lines, MMP-9 
expression was increased compared to non-invasive counterpart. [48] Also MMP-9 
overexpression increased the incidence of metastatic diseases in immunocomprized 
mice. [48] 
The relation between MMP-9 and CDH1 has been investigated but is still not 
clear. One study in epithelial ovarian cancer cells showed that MMP-9 was involved 
in EGF-dependent down-regulation of CDH1 and recombinant MMP-9 or transient 
expression of MMP-9 was sufficient to reduce CDH1 levels in the absence of EGF. 
[52] Incubation of epithelial ovarian carcinoma cells with exogenous MMP-9 
catalyzed CDH1 ectodomain shedding, suggesting posttranslational modification of 
CDH1 function via MMP-9. [53] The soluble CDH1 fragment thus released inhibits 
CDH1 functions in a paracrine way. [54] However, some other studies indicated that 
CDH1 might be the upstream regulator of MMP-9. In invasive bronchial BZR tumor 
cells, expression of CDH1 resulted in decreased MMP-9 both at the mRNA and at the 
protein levels. [55] 
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Chapter 2: Hypotheses 
Hypothesis I: 
EGF treatment will induce LIV-1 expression and decrease CDH1 expression in 
prostate cancer cell lines, DU145 and LNCaP. 
 
Hypothesis II: 
EGF treatment will stimulate growth of these cells. 
 
Hypothesis III: 
Knockdown of LIV-1 will increase CDH1 expression in DU145 cells. CDH1 
repressors, Snail, Slug and MMP-9 may play essential roles in this process. 
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Chapter 3: Materials and Methods 
3.1 Cell Culture and Subculture:  
Androgen-independent human prostate cancer cells (DU145) and 
androgen-responsive human prostate cancer cells (LNCaP) were obtained from the 
American Type Cell Culture Collection (ATCC, Rockville, MD) and grown as 
recommended in 5% CO2 at 37˚C and 95% humidity. The cells were maintained in 
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal 
bovine serum. T-75 flasks were used to maintain DU145 and LNCaP cells in 15 ml of 
media. When the cells reached confluency, the media was removed and the cell 
monolayer was rinsed with 5 mL of Phosphate Buffered Saline (PBS). To detach the 
cells, 3 ml of 1XTE (0.05% Trypsin / 0.53 mM EDTA) was added to the cell layer 
and incubated for 5 minutes. Once the cells were observed to be detached, 7 ml of 
media was added to the cell suspension. This 10 ml of cell suspension was next 
aliquoted to two T-75 flasks. Fresh media (10 ml) was added to each flask after the 
division. 
 
3.2 EGF treatment 
DU145 and LNCaP cells were grown in T-25 flasks until they reached an 
approximately 60% confluency. Cells were incubated in serum-free RPMI for 24hrs. 
Serum-free RPMI with or without 10ng/ml of EGF (Sigma, St. Louis, MO) was used 
for another 24 hours and then RNA and proteins were extracted. Three flasks were 
assigned to each treatment group---non-EGF as control, and 10 ng/ml EGF. 
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3.2 Transfection 
pLKO.1-puro vector plasmids (Sigma, St. Louis, MO) with short hairpin RNA 
(shRNA) specifically targeting the LIV-1 gene were utilized for the transfection 
process. pLKO.1-puro non-target shRNA control vector plasmids were used as 
control. The pLKO.1-puro shRNA plasmids contained a puromycin selection marker 
for stable transfection. The whole plasmid with shRNA targeting LIV-1 was 
transfected into DU145 cells with Fugene HD Transfection reagent (Roche Applied 
Science, Indianapolis, USA).  DU145 cells were plated in T-25 flasks with the 
confluency around 80%. Fugene HD transfection reagent, opti-MEM (diluent for 
DNA) and LIV-1shRNA plasmids were taken out, and adjusted to room temperature. 
Plasmids (2 ug) were diluted into 100 uL opti-MEM. 9uL of Fugene HD transfection 
reagent was added to the plasmids-opti-MEM mixture to make the ratio between 
transfection reagent and plasmids 9:2. The transfection complex was mixed and 
incubated for 15 to 40 minutes then added to the prepared DU145 cells. After 3 days 
incubation, media were replaced with normal growth media. Ten ug/ml puromycin 
(Fisher Scientific, Pittsburgh, PA) was added to select the cells with plasmids before 
the RNA and proteins were extracted.  
A titrating test was used to determine the concentration of puromycin for 
transfection selection. Untransfected DU145 cells (2 x 105 ) were plated in each well 
of a 6-well plate containing 3 ml of the growth media with increasing concentrations 
of puromycin (0, 5.0, 7.5, 10.0 and 12.5 µg/ml). Fresh selective media were replaced 
after 2 days. After two additional days, the percentages of surviving cells were 
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counted. Ten and 12.5 ug/ml puromycin were able to kill 100% of the cells, so the 
concentration of puromycin used for selection was determined to be 10 ug/ml.  
 
3.3 Cell Proliferation Assay 
Cell numbers were routinely quantified with a hematocytometer. Cells were 
detached with trypsin. A 50 ul cell suspension, 400 ul PBS and 50 ul trypan blue 
(Sigma, St. Louis, MO) were mixed in a microcentrifuge tube and left at room 
temperature for 5 minutes. A small amount of the trypan blue-cell suspension was 
transferred to a chamber on the hematocytometer. After counting the cells, about 5 x 
104 cells were inoculated in each well of a 96-well plate and returned to the incubator.  
Before the cell proliferation was tested, 120 ul of a mixture of fresh medium and 
CellTiter-Blue reagent (Promega Corporation, Madison, WI) in a ratio of 100:20 were 
used to replace the media in each well. After incubation at 37 °C for 1 hour, the 
96-well plate was transferred to a micro-spectrophotometer and the florescence values 
were read using an excitation wavelength at 560 nm and emission at 590 nm. 
 
3.4 RNA extraction 
Total cellular RNA was extracted from DU145 and LNCaP cells grown in T-25 
flasks using the Trizol reagent (Invitrogen, Carlsbad, CA). The media were decanted 
off and cells were rinsed with 3 ml of PBS. 1XTE (1.5 ml) was next added to detach 
the cells. The detached cells were poured into labeled 15 ml polypropylene tubes and 
centrifuged at 1000 rpm for 3 minutes. After the cell pellets were obtained, 500 µl of 
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Trizol was added to each tube to dissolve the cell pellets. The cell pellets were 
vortexed and transferred to micro-centrifuge tubes and 250 ul chloroform was added. 
The tubes were vortexed and incubated on ice for 3 minutes and then were further 
centrifuged at 4°C in a micro-centrifuge (Eppendorf, New York, NY) at 10,000 X g 
for 21 minutes to separate the aqueous and the organic phases. The dissolved RNA in 
the aqueous phase was carefully pipetted out into a fresh micro-centrifuge tube. To 
precipitate the RNA from the aqueous phase, 500 µl isopropanol (Fisher Scientific, 
Pittsburgh, PA) was added and mixed. After incubation overnight at -20°C, the 
precipitated RNA was obtained through centrifuging at 10,000 rpm at 4°C for 15 
minutes. To get rid of the contaminating salts and proteins, the pellets were then 
washed with 500 µl 75% ethanol, vortexed, and centrifuged at 10,000 rpm for 5 
minutes. The pellets were air dried for 10 minutes to evaporate the alcohol. The dry 
RNA pellets were then dissolved in Diethylpyrocarbonate (DEPC)-treated water 
(Fisher Scientific, Pittsburgh, PA). They were stored at -80°C if they were not to be 
processed immediately for experiments. 
 
3.5 RNA concentration measurements 
The concentrations of RNA in each sample were estimated using a NanoDrop 
1000 Spectrophotometer. (NanoDrop products, Wilmington, DE) Sample 
concentration in ng/ul was based on absorbance at 260 nm and the selected analysis 
constant 40 ng-cm/ul. The ratio of absorbance at 260 and 280 nm was used to assess 
the purity of RNA. A ratio close to 2.0 was accepted as appropriate for RNA.  
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3.6 Two-step Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
Reverse transcription and PCR were performed sequentially in two separate 
reaction tubes using the Qiagen Two-Step RT-PCR kit (Qiagen, Valencia, CA). RNA 
(4ug) was incubated for 5 minutes at 65°C then placed immediately on ice. Oligo-dT 
(1 ul), 4 ul of 5x LongRange RT Buffer, 2 ul of dNTP Mix, 1 ul of LongRange 
Reverse Transcriptase and 0.2 ul of LongRange RNase inhibitor were added to the 
denatured RNA from each sample. RNase-free water was added to make the final 
volume 20 ul. For synthesis of complementary DNA (cDNA), the mixes were 
incubated for 90 minutes at 42°C and then heated at 85°C for 5 minutes to inactivate 
the enzyme.  
Long Range PCR Buffer (5ul of 10x), 2.5ul of dNTP mix, 2ul of forward primer 
solutions, 2ul of reverse primer solutions, 10 ul of Q-Solution, 0.4 ul of LongRange 
PCR Enzyme Mix and 26.1 ul of RNase-free water were thawed and used to make the 
PCR mix, following the manufacturer’s protocol. Template cDNA (2 µl) were added 
to each tube containing the reaction mix. For a simplified hot start, the tubes were 
placed immediately into a thermal cycler that was preheated to 93°C for 3 min and the 
cycling program started with 93˚C for 15 seconds, 62˚C for 30 seconds, and 68˚C for 
1 minute. 
Primers for MMP-9 were designed using PrimerQuest 
(http://www.idtdna.com/Scitools/Applications/Primerquest/). Forward and reverse 
primers were selected with the following criteria: optimal product size (~500), higher 
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GC/AT ratio, and minimal probability of primer dimerization. The NCBI database 
(http://www.ncbi.nlm.nih.gov/) was used to gather the complete sequence information 
of each gene and to predict the PCR product sizes. Sequences of primers for LIV-1, 
CDH-1, Snail, Slug and 18S Primers were obtained from previous published 
literature. [56] The primers were ordered from Integrated DNA Technologies (IDT, 
San Diego, CA). Before usage, a final primer concentration of 10 µM was prepared in 
DEPC treated water. The primers used and their expected product sizes are shown in 
Table 1. 
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Table 1: Specific Primer Sequences 
Gene  Sequence  Product size Cycle numbers 
LIV-1  Forward: 
5’-GGTGATGGCCTGCACAATTTC-3’  
Reverse: 
5’-TTAACGGTCATGCCAGCCTTTAGTA-3’  
161 27 
CDH1  Forward:  
5’-GTCATTGAGCCTGGCATTT-3’  
Reverse: 
5’-GCTTGAACTGCCGAAAAATC-3’  
462 35 
SNAI1  Forward: 
5’-CCAGAGTCAGCCCTTAGTTC-3’  
Reverse: 
5’-AGGAGAGAGTCCAGAGGATG-3’  
284 30 
SNAI2  Forward:  
5’-TCGGACCCACACATTACC-3’  
Reverse: 
5’-CTGGAGCAGAGGTTGTTAGC-3’  
282 30 
MMP-9 Forward: 
5’-TACCACCTCGAACTTTGACAGCGA-3’ 
Reverse: 
5’-ATCGCCAGTACTTCCCATCCTTGA-3’ 
504 30 
18S  Forward: 
5’-GCTTAATTTGACTCAACACGGGA-3’  
Reverse: 
5’-AGCTATCAATCTGTCAATCCT-3’  
84 25 
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In order to obtain an appropriate detection before reaching the plateau of the 
PCR reaction, each pair of primers was tested for its optimal cycle number. The 
thermo cycler was set to run until the cycle number of 35. At the end of 25, 27, 30 and 
32 cycles, 5µl of sample was pipetted out into a 0.2 ml thin-wall PCR tube. The 
samples were next separated on 1% agarose gel. 
 
3.7 PCR Product Gel Electrophoresis 
The amplified samples from two-step RT-PCR were separated by electrophoresis 
through 1% agarose gels (0.5 g of agarose (Invitrogen, Carlsbad, CA)), in 50 ml TBE 
buffer (Fisher Scientific, Pittsburgh, PA) containing 5 µl ethidium bromide (10 
mg/ml). PCR amplified product (5 µl), 1 µl of 10 X loading dye, and 4 µl of distilled 
water were mixed and loaded carefully into each lane of the 1% agarose gel. 100bp 
DNA ladder (New England Biolabs, MA, USA) was added to one of the lanes and run 
alongside the samples to validate the PCR product sizes. The gel was run at 120 volts 
for 30 minutes. After the run was completed, the gel was visualized under UV light 
using a ChemiDoc System (BioRad, Hercules, CA) and the bands quantified using 
Quantity One Software (BioRad, Hercules, CA). 
 
3.8 Protein Extraction 
Cells grown in T-25 flasks were rinsed with 2 ml of PBS and detached with 2 ml 
of 1XTE. The cell suspensions were transferred to 15 ml polypropylene tubes and 
centrifuged at 1000 rpm for 3 minutes. The supernatant was removed and 50 µl of 
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RIPA lysis buffer (Teknova, Hollister, CA) containing 30 µl/ml protease inhibitor 
cocktail (Sigma, St. Louis, MO) was added to the pellets. The resuspended pellets 
were transferred to pre-cooled microcentrifuge tubes after vortexing briefly. The tubes 
were incubated with constant agitation on a platform shaker at 4˚C for 30 minutes. 
Afterwards, the tubes were centrifuged at 10,000 rpm for 10 minutes at 4˚C to pellet 
cell debris. The protein supernatants were transferred into pre-cooled tubes and stored 
at -80˚C. 
 
3.9 Protein Concentration Measurement 
The BCA protein assay (Thermo Fisher Scientific, IL) was used for the 
measurement of protein concentrations. Standards were prepared with albumin and 
absorbance was measured at 562 nm. Protein concentrations were calculated with a 
standard curve after absorbance was measured. RIPA buffer was used to make a five 
times dilution of the sample solution.  
 
3. 10 Western Blot 
A 10% polyacrylamide resolving gel made with 1.5 M TrisHCl was cast and 
milli-Q water was used to remove bubbles. After the gel polymerized for 1 hour, the 
top layer of milli-Q water was removed before a 5% polyacrylamide stacking gel was 
added and allowed to polymerize for 30 minutes. 
Protein solution with 60 µg of protein and loading dye whose volume was half of 
the protein solution were mixed and incubated at 95ºC for 10 minutes to denature the 
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protein. The heated samples were loaded in the wells of the stacking gel alongside a 
Precision plus Kaleidoscope Ladder (5 µl) protein standard (Bio-Rad Laboratories, 
Hercules, CA). The gel was electrophoresed at room temperature in running buffer 
(1X Tris/Glycine: 25 mM Tris, 192 mM Glycine, 0.1% SDS, pH 8.3) at 60 volts for 
30min then switched to 150 volts for 1 hour.  
The gel was removed from the glass plates. Since the molecular weights of 
LIV-1 and CDH1 vary, 42 kD and 75 kD, respectively, the gel was divided into 2 
parts along the 50 kD line and used for detecting the different proteins with different 
primary antibodies. A piece of PVDF membrane was placed on each half of the gel 
removing any bubbles between the gel and the membrane. The gel and membrane 
were sandwiched between sponges and filter paper and placed in the transfer cassette. 
The gel was placed close to the negative side. The transfer cassette was loaded in a 
cartridge and placed in transfer buffer (100 mL of methanol, 700 mL of Milli-Q 
water, and 100 mL of 10X Tris/Glycine (25 mM Tris, 192 mM glycine)). The transfer 
was carried out for 2 hours at 250 mA at 4°C using the Mini Transblot Electrophoretic 
Cell with a stir bar (Bio-Rad Laboratories, Hercules, CA). 
After transfer, the membrane was removed from the transfer cassette and stained 
with Ponceau S to ensure the integrity of the protein and the completeness of the 
transfer. It was then blocked with 20 mL of blocking buffer (0.5% nonfat dry milk in 
TBS/T [0.1% Tween-20 in Tris-buffered saline]) in a tray for one hour at room 
temperature on a platform shaker. The blocking buffer was poured off and the 
membrane was incubated with LIV-1 or CDH-1 primary antibodies (Santa Cruz 
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Biotechnology, CA, USA) overnight on the shaker at 4 ºC. The dilution of LIV-1 and 
CDH-1 rabbit polyclonal IgG antibodies used was 1:500. Both primary antibodies 
were diluted in blocking buffer. The following day, the primary antibody solution was 
removed and the membrane was washed three times with TBS / T (1% Tween-20) for 
5 minutes each wash. After the washes, the goat anti-rabbit IgG-HRP secondary 
antibody (Santa Cruz Biotechnology, CA, USA) was added (1:1000) and incubated 
for 1 hour on the platform shaker. The membrane was rinsed with TBS twice before 
adding the detection reagents. 
Western Blotting Luminol Reagents (Santa Cruz Biotechnology, CA, USA) were 
mixed together. The solution was poured onto the washed membrane and incubated 
for 5 minutes with periodic shaking. The membrane was removed with tweezers and 
was dragged with the protein side down along a piece of Kimwipe to remove excess 
reagents before being inserted between sheet protectors. Light emissions from the 
membrane were detected using the ChemiDoc System (BioRad, Hercules, CA) and 
quantified using Quantity One Software (BioRad, Hercules, CA).  
The membrane with LIV-1 primary antibodies was then incubated with Western 
Re-Probe buffer (GBiosciences, MO) for 30 minutes to strip the LIV-1 primary 
antibodies and then reprobed with β-Actin primary antibodies (Santa Cruz 
Biotechnology, CA) using the same process as before.  
 
3.11 MMP Proteolytic Assay 
Non-target shRNA DU145 cells (5 x 104 ) and LIV-1 shRNA DU145 cells were 
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plated into each well of a 96-well plate. Six hours after plating, the media were 
removed and the cells rinsed with PBS. Cells were then incubated with 50 ul of 
serum-free RPMI. After 20 hours, conditioned media were collected and centrifuged. 
The supernatants were stored at -80°C before being used. Cell number was assessed 
using the Cell-Titer Blue assay to make sure the cell growth rate would not influence 
the MMP assay results. 
A 10% polyacrylamide resolving gel embedded with 0.15% gelatin was made and 
milli-Q water was used to remove bubbles. After the gel polymerized for 1hour, the 
top layer of milli-Q water was removed and a 5% polyacrylamide stacking gel 
without gelatin was added and allowed to polymerize for 30 minutes. 
Conditioned media (15 ul) and 2 ul of loading dye were mixed and incubated at 
room temperature for 10 minutes. The samples were loaded in the wells of stacking 
gel and then electrophoresed in running buffer (1X Tris/Glycine: 25 mM Tris, 192 
mM Glycine, 0.1% SDS, pH 8.3) at 120 volts for 90 minutes at room temperature.  
After electrophoresis, the gel was rinsed with 1% Triton-100 3 times with 5 
minutes each rinse to renature the MMP-9 protein. After incubation with the 
developing buffer (50 mM Tris, 10 mM CaCl2 and 0.02% NaN3) for 20 hours at 37°C, 
the gel was stained with 0.125% Coomassie brilliant blue (BioRad, Hercules, CA) 
then destained until clear bands could be seen. 
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3.12 Effects of DTPA on zinc distribution 
Radioactive 65Zn (ZnCl2; 62.5 MBq/mg) was purchased from Perkin Elmer 
(Shelton, CT). DTPA is an extracellular zinc chelator, which has an impact on the 
zinc distribution between intracellular and extracellular zinc. In primary hepatocytes, 
DTPA reduced the uptake of 65Zn from the medium and increased efflux from 
prelabeled cells. However, in GH3 rat anterior pituitary tumor cells, DTPA reduced 
the uptake of 65Zn from the medium, but promoted the retention of the isotope in the 
prelabeled cells. [57] The isotope indicated the different effects of DTPA between 
primary and transformed cells. 
To study the effects of DTPA on the efflux of 65Zn in DU145 cells, cells were 
plated in T-25 flasks and grown to about 75% confluency. The cells were then 
prelabeled in growth media containing around 4.5 kcpm 65Zn for 48 hours. 
Afterwards, the cells were provided with normal fresh media with or without 50uM 
DTPA for another 48 hours. The media were then removed and the cells were rinsed 
with PBS. Cells were detached with 1XTE. The 65Zn content of media, and cells were 
quantified by gamma spectroscopy (Cobra II System, Packard, Meriden, CT). 
 
3.13 Statistical Analyses 
One way ANOVA with Bonferroni’s post hoc test (SPSS version 17.0) was used 
to analyze data from all experiments. An α-level of p < 0.05 was considered 
statistically significant. 
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Chapter 4: Results 
4.1 The Effects of EGF on LIV-1 and CDH1 Expression in DU145 and 
LNCaP cells 
The effects of 24 hours EGF treatment on LIV-1 and CDH1 expressions were 
investigated in DU145 and LNCaP cells. EGF increased the protein expression of 
LIV-1 by about 25% and decreased mRNA and protein expressions of CDH1 to 
approximate 60% in both DU145 (Figure 1) and LNCaP (Figure 2) cells. No change 
of LIV-1 mRNA was observed in either DU145 or LNCaP cells. Cells treated with 
serum-free medium without EGF were used to normalize expression. 
 
4.2 Knockdown of LIV-1 with shRNA in DU145 cells 
MISSION® pLKO.1-puro vector plasmids with sequences specifically targeting 
LIV-1 were used to knockdown LIV-1 expression in DU145 cells. MISSION® 
pLKO.1-puro non-target shRNA control vectors were used as control. Compared to 
the non-target shRNA control, LIV-1shRNA vectors decreased the LIV-1 mRNA and 
protein expression in DU145 cells by around 40% (Figure 3). 18S RNA and β-actin 
were chosen as the housekeeping gene and protein, respectively and were not affected 
by LIV-1shRNA. Non-target shRNA transfected cells were used to normalize 
expression. 
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4.3 The Effects of Knockdown on Snail, Slug and MMP-9 mRNA 
Expression in DU145 cells 
The effects of LIV-1 knockdown on Snail, Slug and MMP-9 mRNA expression 
were investigated in DU145 cells (Figure 4). There was no change in Slug mRNA 
expression in LIV-1 knockdown cells, compared with non-target shRNA transfected 
cells. LIV-1 knockdown, however, decreased the expression of Snail mRNA by 
approximately 60% whereas it decreased mRNA expression of MMP-9 by 40%.  
  
4.4 Effects of EGF on DU145 and LNCaP cell proliferation 
24 hours of 10ng/ml EGF treatment increased the cell growth rates of both 
DU145 and LNCaP cells, by around 20% and 35%, respectively. The readings for 
non-EGF treated cells were set up as 100% and the EGF-treated cells were compared 
to the non-EGF treatment values. (Figure 5) 
 
4.5 Effects of LIV-1 knockdown on DU145 cell proliferation 
LIV-1shRNA knockdown in DU145 cells significantly inhibited cell growth to 
around 85% at 48 hours, compared with non-target shRNA transfected cells. The 
readings acquired at 6 hours after plating were set up as 100% for both non-target and 
LIV-1 shRNA transfected DU145 cells. The readings at 24 hours and 48 hours were 
compared to the 6 hour values. (Figure 6) 
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Chapter 5: Discussion 
In this study, the relationship between LIV-1 and CDH-1 expression and the 
regulation of LIV-1 by EGF were examined in DU145 and LNCaP prostate cancer 
cell lines. LNCaP and DU145 cells, represent androgen-dependent and 
androgen-independent cells respectively. EGF has been shown to differentially 
regulate CDH1 in estrogen receptor positive and estrogen receptor negative breast 
cancer cell line. [56, 58] EGF treatment increased CDH1 expression in estrogen 
receptor negative MDA-MB-231 breast cancer cells [56], while it decreased CDH1 in 
MCF-7 estrogen receptor negative cells. [58]  
Zinc is essential for various physiological processes and its concentrations are 
under tight homeostatic control. [3] The two families of zinc transporters in humans, 
ZnT and ZIP, are involved in zinc homeostasis. [15] They have also been reported to 
have other roles in the cells. In fact, many of them are also involved in other 
physiological functions. For example, ZnT2 functions in lactation, ZIP14 in the 
hypozincemia of inflammation, ZIP6, ZIP7, and ZIP10 in metastatic breast cancer, 
and ZnT8 in insulin processing and as an autoantigen in diabetes. [15] Therefore, zinc 
transporters have been a major focus for scientific research. The peripheral zone 
glandular secretory epithelium in the prostate accumulates extraordinarily high levels 
of zinc and one most important factor in the development and progression of prostate 
malignancy is the lost ability of the malignant cells to accumulate zinc. [10] Several 
zinc transporters, such as ZIP1, ZIP2 and ZIP3, were down regulated in malignant 
prostate cancer cells compared to normal prostate cells. [31, 32]  
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The relationship between the zinc influx transporter, LIV-1, and cancer 
progression has been investigated in breast cancer and prostate cancer. LIV-1 is 
expressed widely, mainly in hormonally controlled tissues such as breast, prostate, 
placenta, kidney, pituitary and corpus callosum. [27] LIV-1 has been identified as a 
gene whose expression is stimulated by estrogen treatment in MCF-7 and ZR-75 
breast cancer cells. [27] In zebrafish gastrula organizer, LIV-1 was shown to control 
EMT by being a downstream target of the transcription factor STAT3. [21] Loss of 
CDH1 expression appears to be strongly involved in EMT since there is a direct link 
between lack of CDH1 production and loss of the epithelial phenotype. [41] 
Down-regulation of CDH1 is associated with cell–cell dissociation and invasion in 
various cancer models. [40] A reduced level of CDH1 is regarded as a characteristic 
of EMT. [40]  
One study found that interruption of EGFR signaling cascades results in an 
inhibition of the growth of both androgen-responsive MDA Pca 2a, MDA Pca 2b and 
LNCaP cells and androgen-independent DU145 and PC3 prostate cancer cells. This 
was accompanied by a blockade of the progression from G1 into S phase. [59] EGF 
treatment could activate the EGFR signaling pathway and stimulate cell growth. In 
the current study, EGF treatment significantly stimulated cell proliferation rates of 
both DU145 and LNCaP after 24 hours. Suppressed cell growth by LIV-1 knockdown 
in DU145 was also found in our study. In HeLa cells, LIV-1 down-regulation also 
inhibited cell growth. [60] EGF treatment induced LIV-1 and cell growth, but it is 
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unclear, to which extent, the increased cell growth by EGF is due to the greater LIV-1 
protein expression by EGF.  
In this study, we investigated whether EGF regulated CDH1 through LIV-1 in 
prostate cancer cells. EGF treatment did not alter LIV-1 mRNA expression. However, 
at the protein level, EGF did induce LIV-1. The induction of LIV-1 protein expression 
but not mRNA expression by EGF indicated post-transcriptional regulation. Effects of 
EGF on post-transcriptional regulation and protein turnover have been reported in 
several studies. [61, 62] EGF regulation of EGFR mRNA and protein in human 
prostate cancer cell lines was found to occur at multiple transcriptional and 
post-transcriptional levels. EGF regulated EGFR protein turnover by inducing rapid 
disappearance of EGFR protein in LNCaP and DU145 cells with a half-life of 
approximate 120 min, compared to approximate 5 h in control cells. [62] Another 
example is ADAM17, which is a transmembrane metalloprotease involved in the 
proteolytic release of the extracellular domain of many cell surface molecules, a 
process known as ectodomain shedding. EGF treatment led to a marked increase in 
the protein levels of ADAM17, but did not affect the levels of the ADAM17 mRNA. 
It did not affect the ADAM17 protein synthesis but increased the maturation of the 
ADAM17 protein and also increased the protein half life. [61] An investigation in 
human breast cancer patients found that LIV-1 mRNA and protein expression levels 
are weakly correlated in their tumors, indicating posttranscriptional regulations in 
vivo. [33] The up-regulation of LIV-1 protein expression with no change in mRNA 
concentrations in our study suggested posttranscriptional regulation of LIV-1 by EGF 
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in prostate cancer cells.  
Both mRNA and protein levels of CDH1 were measured in the same cells in this 
study. It was found that EGF repressed the expression of CDH1 at both mRNA and 
protein levels, raising the possibility that the expression of CDH1 might be down 
regulated by LIV-1. Knockdown of LIV-1 increased CDH1 expression again 
demonstrating a negative correlation between LIV-1 and CDH1 expressions.  
    We found successful knockdown of LIV-1 in DU145 was sufficient to increase 
the CDH1 amount. CDH1 repressors, Snail and Slug, have been proposed as targets of 
LIV-1 in human cervical cancer cell line HeLa. [60] Through stimulating Snail or 
Slug, LIV-1 was proposed to have a negative effect on the expression of CDH1. 
However, LIV-1 knockdown increased Slug and decreased CDH1 expression in 
MDA-MB-231 breast cancer cells, while it did not alter Snail expression. [56] In this 
study, we found decreased mRNA expressions of Snail, but not Slug, in LIV-1 
knockdown cells. These results suggested that Snail may mediate the relationship 
between LIV-1 and CDH1 in prostate cancer cells.  
MMP-9 is known to play a role in angiogenesis, tumor growth and metastasis. 
[48] Overexpressed LIV-1 in prostate cancer cells, ARCaP, through transfection 
resulted in elevated MMP-9 proteolytic enzyme activity and decreased CDH1 
expression. [35] The ability to stimulate MMP-9 proteolytic enzyme activity has been 
proposed to be another pathway by which LIV-1 promoted EMT transition. However, 
the relationship between MMP-9 and CDH1 is still not clear. One study in epithelial 
ovarian cancer cells showed that transient expression of MMP-9 was sufficient to 
 44 
 
reduce CDH1 levels. [52] Incubation of epithelial ovarian carcinoma cells with 
exogenous MMP-9 increased shedding of the CDH1 ectodomain, suggesting 
posttranslational modification of CDH1 function by MMP-9. [53] However, some 
other studies have indicated that CDH1 might down regulate MMP-9. In highly 
invasive bronchial BZR tumor cells, CDH1 expression is absent. Compared with 
CDH1 negative clones, MMP-9 decreased both at the mRNA and at the protein levels 
in transfected CDH1-positive clones. [55] Decreased MMP-9 mRNA expression and 
proteolytic activity were observed in LIV-1 knockdown DU145 cells. It appears that 
LIV-1 influences the cells migratory and invasive properties through both CDH1 and 
MMP-9. 
 Normal cells and cancer cells responded to DTPA, as an extracellular zinc 
chelator, in different ways. DTPA promoted efflux of 65Zn from rat primary 
hepatocytes and pituitary cells, while it increased its retention in rat hepatoma and 
anterior pituitary tumor cells. [57] More zinc was retained in the DTPA-treated 
DU145 cells in our study, suggesting that even though prostate cancer cells lose their 
ability to accumulate high zinc, zinc deprivation still may induce its ability to 
accumulate zinc, in common with other cancer cell lines. 
 Post-transcriptional regulation of LIV-1 by EGF was found in this study. More 
work can be done to look into the precise mode of this regulation, for instance 
whether EGF increases the translation of LIV-1 or increases protein stability. In 
addition, it would be useful to show at what time point the LIV-1 and CDH1 
expression starts to show alterations in response to EGF. Other growth factors, such 
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as insulin growth factor may also be able to regulate CDH1 through LIV-1.  
In summary, as illustrated in Figure 9, this study showed that LIV-1 was involved 
in EGF-dependent down-regulation of CDH1 and knockdown of LIV-1 was sufficient 
to induce CDH1 levels in the absence of EGF by repressing CDH1 repressor Snail in 
prostate cancer cells. Another tumor metastasis marker MMP-9 was also inhibited 
with the LIV-1 knockdown, which confirmed the role of LIV-1 in prostate cancer 
progression.
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Figure 9: Schematic illustrating the relationship between LIV-1 and CDH1 
in current study 
EGF 
 
LIV-1(post-transcriptioal induction) 
     
Snail 
 
CDH1                                          MMP-9 
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